The National Institutes of Health (NIH) has awarded EpiVax with a Small Business Innovation Research (SBIR) grant of $324,980. The company is going to use the funding to further develop its Personalized Immunogenicity Assessment (PIMA) tool, designed to assess risk of enzyme replacement therapy failure in patients with…
Risk factors
Recent Posts
- Our family’s experience with Pompe disease is just one of many
- Use of methotrexate may make Pompe treatment more effective, per study
- 5 years strong: Combo LOPD therapy preserves walking and lung function
- You’re not failing if you can’t remember every detail about your child
- Muscle damage begins before visible changes appear in LOPD